Adverse Events During Plateletpheresis Donation

Abstract

I read the publication on “Underreporting of mild adverse events
(AEs) during plateletpheresis donations” with a great interest.
Kansay noted that “it is recommended to discuss and create
a system of hemovigilance for AE in donations with special
consideration to mild AE which are usually underreported.
[1]”
In clinical practice, the AE might be unexpected but it should
not think that it is not preventable. In the present report by
Kansay,[1] the incidence was reported. However, it is not clear
on how the incidence could be derived. How the AE can be
observed and recorded. In details, it is also questionable how
to judge an AE is mild or severe. In fact, the monitoring of
AE is the basic necessary process in either pharmacological or
nonpharmacological management of the patients. The reporting
of the event is useful for recording. However, it should not
forget a more important necessary process, the planning for
preventive and corrective actions. For any centers that severe
donations, there must be the quality management system that
should described work instructions for the practitioners ranging
from pre‑, during‑and post‑donation phase.[2] For any clinical
settings, there must be standard procedure for observation and
monitoring of AE. There should be standard recording process
and/or form. Also, there should be the specific protocol for
management of any possible observed AE. For the report by
Kansay,[1] the data on these interesting points is lack.